Primary Membranous Nephropathy Study
Primary Membranous Nephropathy Trials in Phoenix
Aventiv Research is currently participating in a primary membranous nephropathy study at our Phoenix, AZ location. Primary membranous nephropathy (pMN) is a kidney-specific, autoimmune disease. Advances in drug therapy are key to treating this disease in its early stages and preventing further damage.
Primary Membranous Nephropathy Clinical Trial
The primary objective of this study is to evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of obinutuzumab as compared to tacrolimus, two FDA approved drugs, in patients with pMN. This is an open-label study, patients will get either obinutuzumab or tacrolimus. You maybe be eligible to participate in this study if you:
- Are 18 to 75 years of age
- Have a diagnosis of pMN according to renal biopsy prior to or during screening
Ready to Volunteer?
Volunteer today to see if you qualify for our primary membranous nephropathy study. *Qualified volunteers may be compensated for time and travel.